New Data on Bimekizumab in Psoriatic Arthritis
(MedPage Today) -- At the American College of Rheumatology annual meeting, new data was presented on the long-term safety and efficacy of bimekizumab (Bimzelx), a dual interleukin (IL)-17A/F inhibitor, in active psoriatic arthritis.
In this second...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news